One Eleven Interactive, Inc

Innovative marketing programs for the pharmaceutical industry

One Eleven Interactive, Inc Introduction How to be a smart mother, learn to love your son, learn how to have a family

How to be a smart mother, learn to love your son, learn how to have a family

Tonix Pharma has launched a new drug treatment for bipolar disorder, with a trial set to begin this week in the UK.

The treatment aims to improve the quality of life of people with bipolar disorder.

Tonix, which is the world’s largest maker of antipsychotic drugs, says that about 25% of people diagnosed with bipolar have no symptoms at all, but in the case of people who are bipolar, there are serious side effects including mood swings, sleep disturbances, and suicidal thoughts.

The drug, called the SZF-100, was developed by Dr Stephen Fauci, who is also the co-founder of Tonix Pharmaceuticals.

He says it has already been approved in Australia, France, Canada, Germany, Italy, Japan, New Zealand, the United Kingdom and the US.

The company says the trial, which has just begun, will test the drug on people with a diagnosis of bipolar disorder and is expected to be completed by the end of 2019.

The trial will involve the use of a pill, called an antipsychotics patch, which can be administered for up to three months.

The SZB-100 pill, which contains an array of drugs, including serotonin reuptake inhibitors (SSRIs), benzodiazepines, antidepressants and anti-psychotics, can be taken by itself, or as part of a combination of two other medications.

It is hoped that the Sazanavir treatment could be used in people with milder forms of bipolar, such as those with bipolar II or III.

In a press release, Tonix says the SzB-101 patch is designed to target people who have a mild or moderate bipolar disorder who are also having suicidal thoughts or who are struggling with mood swings.

The researchers are currently working with a number of research organisations, including Imperial College London, to assess the effectiveness of the drug.

The team at Tonix is also working with leading British research centres and universities, including University College London and Imperial College, to determine whether or not the Szb-101 pill works in people who need medication to manage their mood swings and suicidal behaviour.

The results of the trials are due by the middle of next year. has more information about Tonix’s new drug.

TopBack to Top